Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

Rhea-AI Summary

Agios Pharmaceuticals (Nasdaq: AGIO) will host a conference call and live webcast on February 23, 2023, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2022 financial results. The event will be accessible via the Investors section on Agios’s official website. The company is known for its role in cellular metabolism and its marketing of a first-in-class pyruvate kinase activator for adults with PK deficiency, a rare hemolytic anemia. Agios is also advancing a clinical pipeline targeting various blood disorders, including sickle cell disease and thalassemia.

Positive

• Agios is advancing a robust clinical pipeline targeting rare diseases.
• The company offers the first disease-modifying therapy for PK deficiency.

Negative

• None.

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and year end 2022 financial results and other business highlights.

A live webcast can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:
Adam Bero, Ph.D.
Kendall Investor Relations
abero@kendallir.com

Media:
Jessica Rennekamp
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com

FAQ

When will Agios Pharmaceuticals report its Q4 and year-end 2022 financial results?

Agios Pharmaceuticals will report its Q4 and year-end 2022 financial results on February 23, 2023.

How can I access the Agios Pharmaceuticals conference call?

The Agios Pharmaceuticals conference call can be accessed through the Investors section of their official website.

What is the main focus of Agios Pharmaceuticals?

Agios Pharmaceuticals focuses on pioneering therapies for rare diseases, particularly in cellular metabolism.

What products does Agios Pharmaceuticals market?

Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency.